Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer

Thyroid

Volumn 21, Issue 4, 2011, Pages 451-454

  Toubert, Marie Elisabeth ^a   Vercellino, Laetitia ^a   Faugeron, Isabelle ^a   Lussato, David ^a   Hindie, Elif ^a   Bousquet, Guilhem ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; ATORVASTATIN; CLOPIDOGREL; CREATINE KINASE MB; FLUORODEOXYGLUCOSE F 18; IMATINIB; IODIDE; IODINE 131; PERINDOPRIL; RADIOACTIVE IODINE; SORAFENIB; THYROGLOBULIN; TROPONIN I;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; ANTIHYPERTENSIVE THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CARDIOGENIC SHOCK; CARDIOVASCULAR RISK; CASE REPORT; CERVICAL LYMPH NODE; CHRONIC MYELOID LEUKEMIA; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY CIRCUMFLEX BRANCH; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG FATALITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; HAND FOOT SYNDROME; HEART FAILURE; HEART INFARCTION; HEART LEFT ANTERIOR BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HUMAN TISSUE; LUNG BIOPSY; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MULTIMODALITY CANCER THERAPY; OBESITY; POLYNESIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SUDDEN DEATH; THORAX PAIN; THYROGLOBULIN BLOOD LEVEL; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TREATMENT RESPONSE; WHOLE BODY SCINTISCANNING;

ACUTE CORONARY SYNDROME; BENZENESULFONATES; FATAL OUTCOME; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIDINES; PYRIMIDINES; THYROID NEOPLASMS;

EID: 79954455226     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2010.0270     Document Type: Article

References (16)

1. Sobin LH, Wittekind Ch (eds) UICC 2002 TNM Classifica-tion of Malignant Tumors. 6th edition. New York: John Wiley & Sons pp 52-56.
2. Kim S., Rosen L.S., Cohen E.E., Cohen R.B., Forastiere A., Silva A.M., Liau K.F., Archer R.L., Bycott P., Vokes E.E. 2006 A Phase II study of axitinib (AG-013736), a potent inhibitor of VEGFRs, in patients with advanced thyroid cancer. Proc Am Soc Clin Oncol 24: 18S (abstract 5529)
3. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oos-terom AT, Christian MC, Gwyther SG 2000 New guide-lines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216.
4. Hoftijzer H, Heemstra KA, Morreau H, Stokkel MP, Corss-mit EP, Gelderblom H, Weijers K, Pereira AM, Huijberts M, Kapiteijn E, Romijn JA, Smit JW 2009 Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 161:923-931.
5. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE, Jr., Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH 2009 Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675-1684.
6. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS 2008 Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714-4719.
7. Force T, Krause DS, Van Etten RA 2007 Molecular mecha-nisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7:332-344. (Pubitemid 46652481)
8. Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M, Schmidinger H 2008 Car-diac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 26:5204-5212.
9. Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ, Rosenzweig A, Salomon RN, Van Etten RA, Alroy J, Durand JB, Force T 2006 Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12:908-916. (Pubitemid 44175142)
10. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM 2007 Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134. (Pubitemid 46089673)
11. Hasinoff BB, Patel D 2010 Mechanisms of myocyte cyto-toxicity induced by the multikinase inhibitor sorafenib. Cardiovasc Toxicol 10:1-8.
12. Fazel S, Cimini M, Chen L, Li S, Angoulvant D, Fedak P, Verma S, Weisel RD, Keating A, Li RK 2006 Cardioprotec-tive c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J Clin Invest 116:1865-1877. (Pubitemid 44033311)
13. Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, Mekhail T, Bukowski RM, Budd GT, Triozzi P, Borden E, Ivy P, Chen HX, Dolwati A, Dreicer R 2009A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res 15:6277-6283.
14. Weber WA 2009 Assessing tumor response to therapy. J Nucl Med 50 Suppl 1:1S-10S.
15. Tio RA, Dabeshlim A, Siebelink HM, de Sutter J, Hillege HL, Zeebregts CJ, Dierckx RA, van Veldhuisen DJ, Zijlstra F, Slart RH 2009 Comparison between the prognostic value of left ventricular function and myocardial perfusion re-serve in patients with ischemic heart disease. J Nucl Med 50:214-219.
16. Rominger A, Saam T, Wolpers S, Cyran CC, Schmidt M, Foerster S, Nikolaou K, Reiser MF, Bartenstein P, Hacker M 2009 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med 50:1611-1620.